相关实验视频
Updated: Jun 27, 2025

08:50
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
6.9K
为肺癌接受免疫治疗的患者的营养状况变化和瘤反应之间的相关性 (NUTIMMUNO研究)
Marie Mahé1, Valérie Seegers2, Damien Vansteene3
1Institut de Cancérologie de L'Ouest, 49055, Angers, France. marie.mahe@ico.unicancer.fr.
概括
在接受免疫检查点抑制剂 (ICI) 的肺癌患者中保持良好的营养状况 (NS) 会改善治疗反应和存活率. 在NS的早期改善不能预测更好的瘤反应或整体存活率 (OS).
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 营养科学 营养科学
背景情况:
- 营养不良在肺癌患者中普遍存在,并影响预后.
- 免疫检查点抑制剂 (ICI) 是非小细胞肺癌 (NSCLC) 的关键治疗方法.
- 营养状况 (NS) 是癌症的独立预后因素.
研究的目的:
- 调查ICI治疗期间NS的早期改善是否与6个月后瘤反应相关.
- 评估接受ICI的NSSCLC患者的NS进化和结果之间的关联.
主要方法:
- 对106名开始ICI的NSCLC患者的回顾性审查.
- 在基线 (M0) 和3个月 (M3) 使用HAS 2019标准 (BMI,体重减轻,白蛋白) 评估NS.
- 分析NS类别 (营养良好,营养不良,非常营养不良) 和它们的演变.
主要成果:
- 39.6%的患者在基线时营养不良; 43.3%在3个月后.
- 基线时营养良好的患者的整体存活时间 (OS) 和无进展存活时间 (PFS) 较长.
- 在ICI治疗期间保持良好的营养与与营养不良或恶化的组相比,更好的ICI成功率和OS相关.
结论:
- 在早期ICI治疗期间保持良好的NS与更好的OS和NSCLC的客观反应率有关.
- 在NS的早期改善似乎不能预测有利的瘤反应或改善的OS.
- 营养状况管理对于优化接受ICI治疗的NSCLC患者的结果至关重要.
更多相关视频
09:01Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
327
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.5K
相关概念视频
Tumor Immunotherapy
520
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
520
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Cancer Survival Analysis
345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345